# US 2023/0058545 A1 · Hck as a therapeutic target in myd88 mutated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058545 A1
- Document ID: US20230058545A1
- Status: Published application
- Kind: A1
- Application number: 17/767,413
- Filed: 2020-10-07
- Published: 2023-02-23
- Earliest claimed: 2019-10-08
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Steven P. Treon; Nathanael S Gay; Sara Jean Buhriage; Guang Yang; Jinhua Wang; Li Tan
- Web page: https://patentgrep.com/patent/US20230058545A1

## CPC

- C07D 231/38: Nitrogen atoms (nitro radicals C07D231/16)
- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 471/04: Ortho-condensed systems
- C07D 473/34: attached in position 6, e.g. adenine
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
R is optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —O-optionally substituted carbocyclyl, —CH2—O-optionally substituted carbocyclyl, —O-optionally substituted aryl, —CH2—O-optionally substituted aryl, —O-optionally substituted heteroaryl, or —CH2—O-optionally substituted heteroaryl;
R1 is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
each occurrence of R2 is independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —ORa, —N(Ra)2, or —SRa, wherein Ra is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom;
each occurrence of R3 is independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —ORb, —N(Rb)2, or —SRb, wherein Rb is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom;
J is a bond or alkynylene;
m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, as valency permits;
n is 1, 2, 3, 4, 5, 6, 7, or 8, as valency permits;
A is an optionally substituted mono- or bicyclic-heteroaryl, or optionally substituted bicyclic heterocyclyl; and
provided that when J is a bond, R is substituted phenyl, R1 is methyl, R2 is H, and R3 is H, then ring A is not of the formula:

### Claim 2 (depends on 1)

The compound of claim 1, wherein ring A is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
R4 is independently selected from hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, —CN, —SCN, —NO2, —C(═O)Rb, —C(═O)N(Rb)2, —ORb, —N(Rb)2, —C(═NRb)Rb, —C(═NRb)ORb, —C(═NRb)N(Rb)2, —C(═O)ORb, —NRbC(═O)Rb, —NRbC(═O)ORb,
—NRbC(═O)N(Rb)2, —OC(═O)Rb, —OC(═O)ORb, —OC(═O)N(Rb)2, or —SRb, wherein Rb is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom:
R5 is independently selected from hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, —CN, —SCN, —NO2, —C(═O)Rb, —C(═O)N(Rb)2, —ORb, —N(Rb)2, —C(═NRb)Rb, —C(═NRb)ORb, —C(═NRb)N(Rb)2, —C(═O)ORb, —NRbC(═O)Rb, —NRbC(═O)ORb,
—NRbC(═O)N(Rb)2, —OC(═O)Rb, —OC(═O)ORb, —OC(═O)N(Rb)2, or —SRb, wherein Rb is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom;
R6 is independently selected from hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, —CN, —SCN, —NO2, —C(═O)Rb, —C(═O)N(Rb)2, —ORb, —N(Rb)2, —C(═NRb)Rb, —C(═NRb)ORb, —C(═NRb)N(Rb)2, —C(═O)ORb, —NRbC(═O)Rb, —NRbC(═O)ORb,
—NRbC(═O)N(Rb)2, —OC(═O)Rb, —OC(═O)ORb, —OC(═O)N(Rb)2, or —SRb, wherein Rb is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom;
X1 and X2 are independently ═N—, or ═C(Rc)—, as valency permits, wherein Rc is hydrogen, halogen, or substituted or unsubstituted C1-6 alkyl;
X3 is N, C, or C(Rd), as valency permits, wherein Rd is hydrogen, halogen, or substituted or unsubstituted C1-6 alkyl; and
p is 0 or 1, as valency permits.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of Formula (II):

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 3)

The compound of claim 3, wherein
(a) X1 is ═N—; or
(b) X1 is ═C(H)—; and
(c) X2 is ═N—; or
(d) X2 is ═CH—; and
(e) X3 is N; or
(f) X3 is C; or
(g) X3 is CH; and
(h) X4 is ═N—; or
(i) X4 is ═CH—.

### Claim at position 6

7-8. (canceled)

### Claim 9 (depends on 3)

The compound of a claim 3, wherein the compound is of the formula:

### Claim at position 8

10-11. (canceled)

### Claim 12 (depends on 3)

The compound of claim 3, wherein
(a) is 0; or
(b) p is 1; and
(c) J is a bond; or
(d) J is alkynylene; and
(e) R is optionally substituted phenyl; or
(f) R is 4-phenoxyphenyl; or
(g) R is —CH2—O-substituted phenyl; or
(h) R is —CH2—O-unsubstituted phenyl; and
(i) R1 is optionally substituted alkyl; or
(j) R1 is unsubstituted methyl; and
(k) R2 is H; and
(1) R3 is H; and
(m) R4 is H; or
(n) R4 is —C(O)NH2; and
(o) R5 is NH2.

### Claim at position 10

13-48. (canceled)

### Claim 49 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, selected from the formula:

### Claim 50 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable excipient.

### Claim 51 (depends on 50)

The pharmaceutical composition of claim 50 further comprising an additional pharmaceutical agent.

### Claim at position 14

52-54. (canceled)

### Claim 55 (depends on 51)

The pharmaceutical composition of claim 51, wherein the additional pharmaceutical agent is venetoclax.

### Claim 56

(canceled)

### Claim 57 (depends on 1)

A method of treating a disease associated with an MYD88 mutation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.

### Claim 58 (depends on 57)

The method of claim 57, wherein the disease is a proliferative disease.

### Claim 59 (depends on 58)

The method of claim 58, wherein the proliferative disease is cancer.

### Claim at position 20

60-64. (canceled)

### Claim 65 (depends on 59)

The method of claim 59, wherein the cancer is Waldenstrom's macro-globulinemia.

### Claim at position 22

66-67. (canceled)

### Claim 68 (depends on 6759)

The method of claim 6759, wherein, the cancer is activated B-cell-like (ABC)-DLBCL.

### Claim at position 24

69-89. (canceled)

### Claim 90 (depends on 59)

The method of claim 59, wherein the cancer is associated with aberrant activity of one or more of HCK, -BTK, and LYN in a subject.

### Claim 91 (depends on 90)

The method of claim 90, wherein the aberrant activity is overexpression.

### Claim at position 27

92-106. (canceled)
